Olga Elizarova

Dr. Olga Elizarova

Play Collaborate Change
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
CWCaroline Wright
Caroline Wright
PWPhilippa Williams
Philippa Williams
OEOlga Elizarova
Olga Elizarova
JDJennifer Dahne
Jennifer Dahne
Jiang BianJiang Bian
Jiang Bian
ATAndy SL Tan
Andy SL Tan
Objectives To assess the effect of exposure to misinformation about e-cigarette harms found on Twitter on adult current smokers’ intention to quit smoking cigarettes, intention to purchase e-cigarettes and perceived relative harm of e-cigarettes compared with regular cigarettes. Setting An online randomised controlled experiment conducted in November 2019 among USA and UK current smokers. Participants 2400 adult current smokers aged ≥18 years who were not current e-cigarette users recruited from an online panel. Participants’ were randomised in a 1:1:1:1 ratio using a least-fill randomiser function. Interventions Viewing 4 tweets in random order within one of four conditions: (1) e-cigarettes are just as or more harmful than smoking, (2) e-cigarettes are completely harmless, (3) e-cigarette harms are uncertain, and (4) a control condition of tweets about physical activity. Primary outcomes measures Self-reported post-test intention to quit smoking cigarettes, intention to purchase e-cigarettes, and perceived relative harm of e-cigarettes compared with smoking. Results Among US and UK participants, after controlling for baseline measures of the outcome, exposure to tweets that e-cigarettes are as or more harmful than smoking versus control was associated with lower post-test intention to purchase e-cigarettes (β=−0.339, 95% CI −0.487 to –0.191, p<0.001) and increased post-test perceived relative harm of e-cigarettes (β=0.341, 95% CI 0.273 to 0.410, p<0.001). Among US smokers, exposure to tweets that e-cigarettes are completely harmless was associated with higher post-test intention to purchase e-cigarettes (β=0.229, 95% CI 0.002 to 0.456, p=0.048) and lower post-test perceived relative harm of e-cigarettes (β=−0.154, 95% CI −0.258 to –0.050, p=0.004). Conclusions US and UK adult current smokers may be deterred from considering using e-cigarettes after brief exposure to tweets that e-cigarettes were just as or more harmful than smoking. Conversely, US adult current smokers may be encouraged to use e-cigarettes after exposure to tweets that e-cigarettes are completely harmless. These findings suggest that misinformation about e-cigarette harms may influence some adult smokers’ decisions to consider using e-cigarettes. Trial registration number ISRCTN16082420.

JLJessica Liu
Jessica Liu
CWCaroline Wright
Caroline Wright
OEOlga Elizarova
Olga Elizarova
JDJennifer Dahne
Jennifer Dahne
Jiang BianJiang Bian
Jiang Bian
ATAndy SL Tan
Andy SL Tan
There is a gap in knowledge on the affective mechanisms underlying effects of exposure to health misinformation. This study aimed to understand whether discrete emotional responses and perceived relative harm of e-cigarettes versus smoking mediate the effect of exposure to tweets about the harms of e-cigarettes on Twitter and intention to purchase e-cigarettes among adult smokers. We conducted a web-based experiment in November 2019 among 2400 adult smokers who were randomly assigned to view one of four conditions of tweets containing different levels of misinformation. We fitted mediation models using structural equation modeling and bootstrap procedures to assess the indirect effects of exposure to tweets through perceived relative harm of e-cigarettes and six discrete emotions. Our findings support that exposure to tweets about harms of e-cigarettes influence intention to purchase e-cigarettes through perceived relative harm, discrete emotional responses, and serially through emotional responses and perceived relative harm. Feeling worried, hopeful, and happy mediated the effects of condition on intention to purchase e-cigarettes. Feeling scared, worried, angry, and hopeful mediated the effects serially through perceived relative harm. Affective responses and perceived relative harm following exposure to misinformation about e-cigarette harm may mediate the relationship with intention to purchase e-cigarettes among adult smokers.

21 December 2021 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
JLJessica Liu
Jessica Liu
CWCaroline Wright
Caroline Wright
PWPhilippa Williams
Philippa Williams
OEOlga Elizarova
Olga Elizarova
JDJennifer Dahne
Jennifer Dahne
ATAndy SL Tan
Andy SL Tan
Background: Information and misinformation on the internet about e-cigarette harms may increase smokers’ misperceptions of e-cigarettes. There is limited research on smokers’ engagement with information and misinformation about e-cigarettes on social media. Objective: This study assessed smokers’ likelihood to engage with—defined as replying, retweeting, liking, and sharing—tweets that contain information and misinformation and uncertainty about the harms of e-cigarettes. Methods: We conducted a web-based randomized controlled trial among 2400 UK and US adult smokers who did not vape in the past 30 days. Participants were randomly assigned to view four tweets in one of four conditions: (1) e-cigarettes are as harmful or more harmful than smoking, (2) e-cigarettes are completely harmless, (3) uncertainty about e-cigarette harms, or (4) control (physical activity). The outcome measure was participants’ likelihood of engaging with tweets, which comprised the sum of whether they would reply, retweet, like, and share each tweet. We fitted Poisson regression models to predict the likelihood of engagement with tweets among 974 Twitter users and 1287 non-Twitter social media users, adjusting for covariates and stratified by UK and US participants. Results: Among Twitter users, participants were more likely to engage with tweets in condition 1 (e-cigarettes are as harmful or more harmful than smoking) than in condition 2 (e-cigarettes are completely harmless). Among other social media users, participants were more likely to likely to engage with tweets in condition 1 than in conditions 2 and 3 (e-cigarettes are completely harmless and uncertainty about e-cigarette harms). Conclusions: Tweets stating information and misinformation that e-cigarettes were as harmful or more harmful than smoking regular cigarettes may receive higher engagement than tweets indicating e-cigarettes were completely harmless. Trial Registration: International Standard Randomized Controlled Trial Number (ISRCTN) 16082420; https://doi.org/10.1186/ISRCTN16082420

15 January 2021 in JMIR Preprints
Verified
Preprint
Open access
JLJessica Liu
Jessica Liu
CWCaroline Wright
Caroline Wright
PWPhilippa Williams
Philippa Williams
OEOlga Elizarova
Olga Elizarova
JDJennifer Dahne
Jennifer Dahne
ATAndy SL Tan
Andy SL Tan
BACKGROUND Information and misinformation on the internet about e-cigarette harms may increase smokers’ misperceptions of e-cigarettes. There is limited research on smokers’ engagement with information and misinformation about e-cigarettes on social media. OBJECTIVE This study assessed smokers’ likelihood to engage with—defined as replying, retweeting, liking, and sharing—tweets that contain information and misinformation and uncertainty about the harms of e-cigarettes. METHODS We conducted a web-based randomized controlled trial among 2400 UK and US adult smokers who did not vape in the past 30 days. Participants were randomly assigned to view four tweets in one of four conditions: (1) e-cigarettes are as harmful or more harmful than smoking, (2) e-cigarettes are completely harmless, (3) uncertainty about e-cigarette harms, or (4) control (physical activity). The outcome measure was participants’ likelihood of engaging with tweets, which comprised the sum of whether they would reply, retweet, like, and share each tweet. We fitted Poisson regression models to predict the likelihood of engagement with tweets among 974 Twitter users and 1287 non-Twitter social media users, adjusting for covariates and stratified by UK and US participants. RESULTS Among Twitter users, participants were more likely to engage with tweets in condition 1 (e-cigarettes are as harmful or more harmful than smoking) than in condition 2 (e-cigarettes are completely harmless). Among other social media users, participants were more likely to likely to engage with tweets in condition 1 than in conditions 2 and 3 (e-cigarettes are completely harmless and uncertainty about e-cigarette harms). CONCLUSIONS Tweets stating information and misinformation that e-cigarettes were as harmful or more harmful than smoking regular cigarettes may receive higher engagement than tweets indicating e-cigarettes were completely harmless. CLINICALTRIAL International Standard Randomized Controlled Trial Number (ISRCTN) 16082420; https://doi.org/10.1186/ISRCTN16082420

12 January 2026 in JMIR Preprints
Verified
Preprint
Open access
ANAndrzej Nowojewski
Andrzej Nowojewski
OEOlga Elizarova
Olga Elizarova
ARAnnika Rutgersson
Annika Rutgersson
AZAnna Zarodkiewicz
Anna Zarodkiewicz
YJYunyun Jiang
Yunyun Jiang
RSRobert F. Storey
Robert F. Storey
BACKGROUND Medication nonadherence in patients with myocardial infarction (MI) is a key obstacle to managing cardiovascular disease. However, there is a lack of studies, particularly randomized controlled trials (RCTs), focusing on objective measures of medication adherence behavior. OBJECTIVE This study aimed to (1) characterize daily medication adherence behavior and dose consistency using objective digital bottle cap data in patients post-MI enrolled in the Dapagliflozin in Patients with Myocardial Infarction (DAPA-MI) RCT, (2) identify patient and contextual factors associated with nonadherence, and (3) assess whether dose consistency is associated with adherence over time. METHODS DAPA-MI was a phase 3, double-blind, placebo-controlled RCT evaluating the effect of 10 mg of dapagliflozin versus a placebo given once daily, in addition to standard-of-care therapy, on adults hospitalized for MI. This post hoc analysis used 733,490 timepoints from a digital bottle cap that recorded when study drug bottles were opened. Adherence and dose consistency were evaluated using mixed-effects regression. Adherence was defined at the patient-day level as at least one bottle opening on a given day. Dose consistency was derived from the day-to-day variation in timing of the first recorded opening event. Digital cap data were linked with demographic, clinical, behavioral, and contextual variables to assess factors associated with nonadherence and lower dose consistency over time. RESULTS In total, 2429 participants were included in the analysis. Features associated with lower adherence included age <40 years (odds ratio [OR] 0.47, 99.9% CI 0.23-0.98), current smokers (OR 0.67, 99.9% CI 0.51-0.87), nonworking days, and serious adverse events. Higher adherence was associated with the New York Heart Association (NYHA) functional class III/IV (OR 1.48, 99.9% CI 1.18-1.86), low (<15 min) 7-day average time variance (OR 1.99, 99.9% CI 1.78-2.23), and morning medication use. Lower dose consistency was observed in patients aged 40-50 years (dose consistency ratio [DCR] 1.23, 99.9% CI 1.03-1.47), in current smokers (DCR 1.16, 99.9% CI 1.03-1.31), and on weekends, while patients with severe angina grading (DCR 0.83, 99.9% CI 0.74-0.94) or morning medication use (DCR 0.88, 99.9% CI 0.86-0.90) had higher dose consistency. Patients with early high dose consistency tended to maintain better adherence over time, whereas missed-dose streaks and routine disruptions were associated with worsening consistency. CONCLUSIONS This study demonstrated the value of objective, continuous digital medication adherence behavior monitoring within a large RCT. Unlike studies relying on self-reported or prescription data, it quantified both adherence and dose consistency at scale, revealing a strong association between them. The findings indicate that temporal irregularity of medication taking may serve as a practical behavioral marker for identifying patients at increased risk of future nonadherence. These findings may advance medication adherence behavior research and inform behavior change interventions, remote monitoring strategies, and predictive adherence models. CLINICALTRIAL

21 September 2026 in Journal of Medical Internet Research
Verified
Journal Article
Open access
ANAndrzej Nowojewski
Andrzej Nowojewski
OEOlga Elizarova
Olga Elizarova
ARAnnika Rutgersson
Annika Rutgersson
AZAnna Zarodkiewicz
Anna Zarodkiewicz
YJYunyun Jiang
Yunyun Jiang
RSRobert F. Storey
Robert F. Storey
Background: Medication nonadherence in patients with myocardial infarction (MI) is a key obstacle to managing cardiovascular disease. However, there is a lack of studies, particularly randomized controlled trials (RCTs), focusing on objective measures of medication adherence behavior. Objective: This study aimed to (1) characterize daily medication adherence behavior and dose consistency using objective digital bottle cap data in patients post-MI enrolled in the Dapagliflozin in Patients with Myocardial Infarction (DAPA-MI) RCT, (2) identify patient and contextual factors associated with nonadherence, and (3) assess whether dose consistency is associated with adherence over time. Methods: DAPA-MI was a phase 3, double-blind, placebo-controlled RCT evaluating the effect of 10 mg of dapagliflozin versus a placebo given once daily, in addition to standard-of-care therapy, on adults hospitalized for MI. This post hoc analysis used 733,490 timepoints from a digital bottle cap that recorded when study drug bottles were opened. Adherence and dose consistency were evaluated using mixed-effects regression. Adherence was defined at the patient-day level as at least one bottle opening on a given day. Dose consistency was derived from the day-to-day variation in timing of the first recorded opening event. Digital cap data were linked with demographic, clinical, behavioral, and contextual variables to assess factors associated with nonadherence and lower dose consistency over time. Results: In total, 2429 participants were included in the analysis. Features associated with lower adherence included age <40 years (odds ratio [OR] 0.47, 99.9% CI 0.23-0.98), current smokers (OR 0.67, 99.9% CI 0.51-0.87), nonworking days, and serious adverse events. Higher adherence was associated with the New York Heart Association (NYHA) functional class III/IV (OR 1.48, 99.9% CI 1.18-1.86), low (<15 min) 7-day average time variance (OR 1.99, 99.9% CI 1.78-2.23), and morning medication use. Lower dose consistency was observed in patients aged 40-50 years (dose consistency ratio [DCR] 1.23, 99.9% CI 1.03-1.47), in current smokers (DCR 1.16, 99.9% CI 1.03-1.31), and on weekends, while patients with severe angina grading (DCR 0.83, 99.9% CI 0.74-0.94) or morning medication use (DCR 0.88, 99.9% CI 0.86-0.90) had higher dose consistency. Patients with early high dose consistency tended to maintain better adherence over time, whereas missed-dose streaks and routine disruptions were associated with worsening consistency. Conclusions: This study demonstrated the value of objective, continuous digital medication adherence behavior monitoring within a large RCT. Unlike studies relying on self-reported or prescription data, it quantified both adherence and dose consistency at scale, revealing a strong association between them. The findings indicate that temporal irregularity of medication taking may serve as a practical behavioral marker for identifying patients at increased risk of future nonadherence. These findings may advance medication adherence behavior research and inform behavior change interventions, remote monitoring strategies, and predictive adherence models.